Pharmafile Logo

InVentive Europe

- PMLiVE

AZ and Novartis ‘most exposed’ to Senate pricing proposals

Most expensive therapies will be penalised

- PMLiVE

Lynparza cleared as ovarian cancer maintenance therapy on Cancer Drugs Fund

Deal done with NHS England just weeks after EU approval

- PMLiVE

AstraZenca to appeal NICE rejection of Tagrisso

Pfizer’s Vizimpro wins recommendation

25 Women Leaders in UK Healthcare

Women trailblazers helping to shape the future of healthcare (Part 1)

- PMLiVE

McCann’s Breath of Life diagnostic wins Cannes Lion prize

Grand Prix awarded for first time in three years

- PMLiVE

AZ says Farxiga cuts kidney disease in type 2 diabetes

Helps in SGLT2 inhibitor battle with Jardiance

- PMLiVE

AZ invests more in IO with Transgene oncolytic virus deal

Opportunity for combinations with IO pipeline

- PMLiVE

Brexit clock ticking once again, UK heads for European elections

New deadline gives pharma more time, but no more clarity

- PMLiVE

Lynparza could soon add first line ovarian use in Europe

Also first PARP inhibitor launched in China

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links